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Coronaviruses are pathogens that cause diverse diseases in humans and animals. The studies in 
this dissertation are focused on feline coronavirus (FCoV), ferret coronavirus (FRCoV) and mink 
coronavirus (MCoV). FCoV and FRCoV infections typically cause enteritis in cats and ferrets, 
respectively. However, a 100% fatal systemic disease called feline infectious peritonitis (FIP) 
can develop in some FCoV infected cats and a fatal systemic disease resembling FIP can develop 
in some FRCoV infected ferrets. MCoV causes enteritis which results in significant economic 
loss to mink farmers. No effective vaccine or treatment is available despite the increasing im-
portance of these viral diseases. We have previously reported the synthesis of inhibitors against 
3C-like protease (3CLpro) of FCoV and demonstrated the antiviral efficacy of a 3CLpro inhibi-
tor for treating FIP. FRCoV and MCoV 3CLpro are closely related to FCoV 3CLpro. Therefore, 
we investigated the structure-function relationships of our 3CLpro inhibitors to identify the struc-
tural requirements of inhibitors for FRCoV and MCoV. This is the first report of antiviral com-
pounds against FRCoV and MCoV. We have previously conducted a field trial with a potent 
3CLpro inhibitor, GC376, in cats with naturally occurring FIP. Comparison of the FCoV 3CLpro 
amino acid sequences from the pre- and post-treatment samples in one cat showed amino acid 
changes in 3CLpro. Hence, we generated recombinant 3CLpros carrying the amino acid changes 
and characterized the effects of these amino acid changes in FCoV 3CLpro on its susceptibility 
to GC376. We observed that these amino acid changes did not markedly affect the activity of 
GC376 in fluorescence resonance energy transfer (FRET) assay, explaining the absence of clini-
cal drug resistance in this cat during the field trial.  
iv 
Table of Contents 
 
List of Figures ................................................................................................................................ vi 
List of Tables ................................................................................................................................ vii 
Acknowledgements ...................................................................................................................... viii 
Dedication ...................................................................................................................................... ix 
 Review of Literature ................................................................................................................ 1 1
1.1 Classification of coronaviruses ........................................................................................ 1 
1.2 Genome organization and structure of coronaviruses ...................................................... 2 
1.3 Replication of coronaviruses............................................................................................ 4 
1.4 Structure and function of coronavirus 3CLpro ................................................................ 7 
1.5 Feline coronavirus ............................................................................................................ 9 
1.5.1 Current preventive and therapeutic measures for FIP............................................... 11 
1.6 Ferret and mink coronaviruses ....................................................................................... 13 
1.6.1 Potential therapeutic targets for coronavirus infections ............................................ 15 
1.7 Inhibitors of coronavirus 3CLpro .................................................................................. 15 
1.8 Antiviral resistance ........................................................................................................ 17 
 Protease inhibitors against Ferret and Mink Coronaviruses .................................................. 19 2
2.1      Abstract ......................................................................................................................... 19 
2.2      Introduction ................................................................................................................... 20 
2.3 Materials and Methods ................................................................................................... 22 
2.3.1 3CLpro inhibitors ...................................................................................................... 22 
2.3.2 Cells and viruses ....................................................................................................... 22 
2.3.3 Multiple amino acid sequence alignment of 3CLpros of FCoVs, FRCoVs and 
MCoVs ..................................................................................................................... 23 
2.3.4 Expression and purification of recombinant 3CLpro ................................................ 23 
2.3.5 FRET protease assay ................................................................................................. 24 
2.3.6 3D structural models of FIPV, FRCoV and MCoV 3CLpros ................................... 25 
2.3.7 Cytotoxicity assay ..................................................................................................... 25 
2.3.8 Antiviral effects of the inhibitors in cell culture against FIPV ................................. 26 
2.4 Results ............................................................................................................................ 26 
v 
2.4.1 Multiple amino acid sequence alignment of 3CLpros of FCoVs, FRCoVs and 
MCoVs ..................................................................................................................... 26 
2.4.2 FRET assay of the 3CLpro inhibitors against recombinant 3CLpros of FIPV, 
FRCoV and MCoVs ................................................................................................. 29 
2.4.3 3D structures of 3CLpro of FIPV, FRCoV and MCoV ............................................ 34 
2.4.4 Antiviral effects of the inhibitors on the replication of FIPV in cell culture ............ 39 
2.5 Discussion ...................................................................................................................... 42 
 Characterization of mutations in 3C-like protease from a cat with feline infectious peritonitis 3
treated with a 3C-like protease inhibitor ............................................................................... 46 
3.1 Abstract .......................................................................................................................... 46 
3.2 Introduction .................................................................................................................... 47 
3.3 Materials and methods ................................................................................................... 48 
3.3.1 CT10 ......................................................................................................................... 48 
3.3.2 Analysis of clinical samples from CT10 ................................................................... 49 
3.3.3 Expression and purification of recombinant FCoV 3CLpros from CT10 ................ 50 
3.3.4 FRET assay ............................................................................................................... 52 
3.3.5 3D homology models of FCoV 3CLpros from CT10 ............................................... 53 
3.4 Results ............................................................................................................................ 54 
3.4.1 Analysis of FCoV 3CLpro amino acid sequences from CT10 ................................. 54 
3.4.2 FRET assay with the recombinant 3CLpros and 3CLpro inhibitors ......................... 56 
3.4.3 The 3D structure models for the FCoV 3CLpros from CT10 ................................... 60 
3.5 Discussion ...................................................................................................................... 63 
 References .............................................................................................................................. 66 4
  
vi 
List of Figures 
Figure 1-1: Classification of coronaviruses .................................................................................... 2 
Figure 1-2: Organization of FCoV genome .................................................................................... 4 
Figure 1-3: Cleavage sites and substrate specificity of FCoV 3CLpro .......................................... 6 
Figure 1-4: Monomeric crystal structure of FCoV 3CLpro (PDB accession 4ZRO) ..................... 8 
Figure 2-1: Multiple amino acid sequence alignment of FCoV, FRCoV, MCoVs and TGEV   
3CLpros ................................................................................................................................. 28 
Figure 2-2: The activity of recombinant 3CLpros of FIPV, FRCoV and MCoV in the absence of 
an inhibitor ............................................................................................................................ 29 
Figure 2-3: Superimposed crystal structures of TGEV and FIPV 3CLpros ................................. 36 
Figure 2-4: Superimposition of 3D homology models of FRCoV and MCoV 3CLpros and the 
crystal structure of FIPV 3CLpro ......................................................................................... 37 
Figure 2-5: Enlarged active site of the superimposed FIPV 3CLpro crystal structure and 3D 
homology models of FRCoV and MCoV 3CLpros .............................................................. 38 
Figure 2-6: Dose dependent inhibitory curve of a 3CLpro inhibitor against FIPV in CRFK cells
 ............................................................................................................................................... 40 
Figure 3-1: Multiple amino acid sequence alignment of FCoV 3CLpros from pre-treatment 
sample and necropsy tissues of CT10 ................................................................................... 55 
Figure 3-2: Activity of the recombinant 3CLpros at 30 min in the absence of 3CLpro inhibitors
 ............................................................................................................................................... 57 
Figure 3-3: Effects of GC376 and NPI52 on recombinant 3CLpros in FRET assay .................... 59 
Figure 3-4: The locations of the amino acid changes in the 3CLpro ............................................ 61 
Figure 3-5: The potential hydrogen bonds of N25, A252 and K260 in WT and the alterations in  




List of Tables 
Table 2-1: Structures and the inhibitory activities of the inhibitors for FIPV, FRCoV and MCoV 
3CLpros in FRET assay ........................................................................................................ 33 
Table 2-2: Activities of inhibitors against FIPV and the cytotoxicity of the inhibitors in CRFK 
cells. ...................................................................................................................................... 41 
Table 3-1: Primer sequences used in RT-PCR and cloning of 3CLpro ........................................ 51 
Table 3-2: Nomenclature of recombinant 3CLpros and the primer sequences used in site directed 
mutagenesis ........................................................................................................................... 52 






I would like to extend my heartfelt gratitude to my major advisor Dr. Yunjeong Kim who 
is a constant pillar of support in my academic life as a graduate student. I am deeply thankful for 
her guidance, advice, support and encouragement at all times. 
  
I wish to express my gratefulness to my committee members, Dr. Kyeong-Ok Chang for 
his guidance, advice and encouragement and Dr. Meena Kumari for her advice and encourage-
ment during my study.  
 
My sincere gratitude and appreciation goes to David George for teaching me the lab 
techniques and being patient with my mistakes. This study would not be possible without his 
support and constant encouragement each and every day. 
 
My sincere thanks go to Changin Oh, who was not only a lab partner but also a friend and 
a brother to me throughout these years. 
 
I would also like to thank each and every one who helped me in one way or another dur-
ing my study. 
 
Finally, the tribute of my achievements goes to my parents, sister, pets and colleagues 




I dedicate this dissertation to Dr. Yunjeong Kim, my family, my colleagues and all those 
who helped me. 
  
1 
 Review of Literature 1
 
1.1  Classification of coronaviruses 
 
The order Nidovirales is composed of enveloped, single stranded RNA viruses that infect a wide 
range of animal species including humans. The term ‘nido’ originated from Latin meaning ‘nest’ 
for the characteristic nested sub-genomic mRNAs produced by nidoviruses during replication [1, 
2]. Additionally, conserved genomic organization and large polyproteins are also characteristic 
features of nidoviruses [3]. The order Nidovirales includes Arteriviridae, Mesoniviridae, Ro-
niviridae and Coronaviridae families [4]. The family Coronaviridae is comprised of Coronaviri-
nae and Torovirinae subfamilies [5, 6]. Coronavirinae subfamily is further divided into four gen-
era; alpha, beta, gamma and delta coronaviruses based on the phylogenetic clustering [4] (Fig. 1-
1). Alphacoronaviruses consist of a range of coronaviruses that infect many species, including 
human coronaviruses 229E and NL63, feline coronavirus (FCoV), ferret coronavirus (FRCoV), 
mink coronavirus (MCoV), canine coronavirus (CCoV), porcine epidemic diarrhea virus 
(PEDV), transmissible gastroenteritis virus (TGEV) and several bat coronaviruses including 
HKU8, HKU10 and CDPHE15 [4]. Betacoronaviruses include human coronaviruses HKU1, 
OC43, Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)  and Middle East Respira-
tory Syndrome coronavirus (MERS-CoV) as well as animal coronaviruses such as murine hepati-
tis virus (MHV) and bat coronaviruses HKU4, HKU5 and HKU9 [4]. Gammacoronaviruses in-
fect wild birds and domestic birds such as turkey coronavirus (TCoV) and infectious bronchitis 
virus which infects chicken [7]. In addition, gammacoronavirus SW1 has been identified in a be-
luga whale in association with liver failure and respiratory disease [8]. Deltacoronaviruses in-
2 
clude a variety of avian coronaviruses such as thrush coronavirus HKU12, bulbul coronavirus 
HKU11, sparrow coronavirus HKU17, magpie-robin coronavirus HKU18, night heron corona-
virus HKU19, and common moorhen coronavirus HKU21 [9] as well as porcine coronavirus 









Figure 1-1: Classification of coronaviruses 
Classification of the Coronaviridae family by the International Committee on Taxonomy of Vi-
ruses [4]. 
 
1.2  Genome organization and structure of coronaviruses 
 
Coronaviruses have a non-segmented, single-stranded, positive sense RNA genome of ~ 30kb in 
length, possessing a 5’ cap and a 3’ poly A tail. There are at least 10 open reading frames (ORFs) 
in the genome of a coronavirus [11]. ORF 1 is the largest ORF occupying two thirds of the 5’ 
end of the genome and encodes non-structural proteins which are important for the replication of 
the virus. ORF1 consists of a larger ORF1a and a relatively smaller ORF1b. ORF1a encodes 
polyprotein 1a (pp1a) while polyprotein 1ab (pp1ab) is produced due to a -1 ribosomal 
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frameshifting from ORF1a to ORF1b during translation [12-15] (Fig. 1-2). The remaining one 
third of the genome at 3’ end contains ORFs of four structural genes, spike (S), envelope (E), 
membrane (M), nucleocapsid (N) and accessory genes [12, 16]. The accessory genes of corona-
viruses are located amongst the major structural genes and the numbers of accessory genes are 
group-specific. For instance, FCoV genome encodes 3abc and 7ab accessory genes in ORF3 and 
ORF7, respectively [14, 17]. The organization of the feline coronavirus genome is depicted in 
figure 1-2.  
 
Coronaviruses have a spherically symmetrical structure with club shaped projections of S pro-
teins, which gives the characteristic appearance of a ‘corona’ [12, 18, 19]. Coronavirus is com-
posed of four structural proteins; S, E, M and N proteins. S protein is a membrane glycoprotein 
that forms an N-linked homo-trimer [20]. S protein binds to the cellular receptor and mediates 
virus entry into host cells. The nucleocapsid is composed of N proteins [18, 21], which are heavi-
ly phosphorylated and associated with multiple copies of virus RNA genome. M protein is an 
abundant small transmembrane protein that provides shape to the virion and interacts with the 
nucleocapsid [22]. The small E protein is also a membrane protein which is important for the as-
sembly and release of virions [5]. The E protein of SARS coronavirus also has ion channel activ-
ity, which may play an important role in pathogenesis of virus [23]. Functions of accessory pro-
teins of coronaviruses may differ between virus groups and associate with viral pathogenesis. For 
instance, FCoV genome encodes accessory proteins 3a, 3b, 3c from ORF3 and 7a and 7b from 
ORF7, which are reported to be important for coronavirus replication [14, 17, 24]. FCoV ORF3 













Figure 1-2: Organization of FCoV genome 
ORF 1 is translated into pp1a and pp1ab, which are subsequently processed by viral proteases to 
generate non-structural proteins. ORFs S, E, M and N generate structural proteins and ORFs 3 
and 7 generate accessory proteins.  
 
1.3 Replication of coronaviruses  
 
Coronavirus binding to the host cell receptor and entry are mediated by the S protein. Host re-
ceptors that have been identified for coronaviruses include aminopeptidase N for TGEV, PEDV, 
HCoV-229E and type II FCoV [25-27], angiotensin-converting enzyme 2 for HCoV-NL63 and 
SARS-CoV [28, 29] and dipeptidyl peptidase 4 for MERS-CoV [30].  
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Coronavirus S protein is a class I fusion protein, which comprises an ectodomain, transmem-
brane domain and endodomain. The ectodomain is composed of S1 and S2 domains [20, 31]. 
The N-terminal S1 domain contains the receptor binding domain and C-terminal S2 domain con-
tains the fusion peptide that plays an essential role in fusion of host membrane and virus enve-
lope [32]. Cleavage of S protein into S1 and S2 by host proteases is important in triggering 
membrane fusion by exposing the fusion peptide [33-35]. Following the uncoating of virus nu-
cleocapsid, translation of ORF1 generates ppla and pp1ab, which contain 1-11 and 1-16 non-
structural proteins, respectively. The polyproteins are proteolytically cleaved by 3C-like protease 
(3CLpro) and papain like protease (PLpro) located within the polyproteins to produce functional 
non-structural proteins. PLpro cleaves 1-4 sites in the N terminal region of the polyproteins 
while 3CLpro cleaves at 8-11 sites in the C terminal part of the polyproteins [36] (Fig. 1-3A). 
PLpro has also shown deubiquitylating and deISGylating activities to counteract host immune 
response in SARS-CoV, MERS-CoV and MHV [37-41]. Subsequently, the cleaved non-
structural proteins assemble into a membrane-attached replication-translation complex composed 
of double membrane vesicles consisting of modified rough endoplasmic reticulum derived mem-
branes [42-44]. Genomic and subgenomic RNAs are synthesized from the single stranded posi-
tive RNA genome [45, 46]. Subgenomic mRNAs are translated into structural and accessory pro-
teins. Viral structural proteins enter the endoplasmic reticulum and maturation occurs during 
transport through secretory pathways on endoplasmic reticulum-golgi intermediate compartment 
[43, 47]. Assembled virions are transported onto the cell surface via vesicles and released from 















Figure 1-3: Cleavage sites and substrate specificity of FCoV 3CLpro 
(A) Schematic cleavage map of FCoV polyproteins (adapted from [14]). PP1a is proteolytically 
processed to generate non-structural proteins 1-11 while proteolytic processing of pp1ab gener-
ates non-structural proteins 1-10 and 12-16. The cleavage sites of PLpro (green) and 3CLpro 
(red) are indicated in the map. The putative functions of several non-structural proteins are des-
ignated in the diagram (abbreviations: ADRP - ADP-ribose 1”-phosphatase; RdRp - RNA-
dependent RNA polymerase; HEL - helicase; Exo. N – exonuclease; Endo. N – endoribonucle-
ase; MT - 2’-O-methyltransferase). (B) The amino acids spanning the 3CLpro cleavage sites in 
the polyprotein are marked P5 to P4’ from the N to C termini (adapted from [48]). Cleavage (in-







1.4 Structure and function of coronavirus 3CLpro  
 
Since most of the cleavage sites in the polyprotein are cleaved by 3CLpro, it is also known as the 
main protease of coronaviruses. 3CLpro has a chymotrypsin-like fold resembling chymotrypsin-
like serine proteases and has similar substrate specificity as 3C protease of picornaviruses [51]. 
Each monomeric 3CLpro comprises I, II and III domains. The active site and substrate binding 
site are in a cleft between domains I and II [51-55] (Fig. 1-4) and the active site of 3CLpro con-
tains a catalytic dyad consisting of Cys144 and His41 [50, 51, 55]. The C-terminal domain III is 
reported to be important for dimerization of 3CLpro and dimeric 3CLpro is the active form [51, 
52, 54-59].  
 
The catalytic amino acid Cys144 initiates a nucleophilic attack on the peptide bond of virus pol-
yprotein while His41 acts as a base and proton acceptor [55, 58], initiating proteolytic processing 
of the polyprotein. Substrate specificity is mainly determined by amino acids at the P2, P1 and 
P1’ sites in the polypeptide (Fig. 1-3B). Gln and Leu is preferred at P1 and P2 sites, respectively, 






Figure 1-4: Monomeric crystal structure of FCoV 3CLpro (PDB accession 4ZRO)  
A 3CLpro monomer consists of domain I, II and III. The catalytic residues His41 and Cys144 are 
indicated in red at the catalytic center between domain I and II. Domain II and III are connected 
through an inter domain loop. The active form of 3CLpro is a dimer which requires interactions 
between the C terminal residues in domain III and the residues in the N terminal finger of do-





1.5 Feline coronavirus 
 
FCoVs are important pathogens of members in the Felidae family. FCoVs are divided into two 
serotypes, type I and type II. All Type I FCoVs sequences are of feline origin whereas type II 
FCoVs are recombinants between FCoV and CCoV [62-64]. Type I is predominant throughout 
the world and type II occurs less frequently [65-69]. Co-infection of both types has also been 
identified [66, 68, 69]. Type I is very difficult to grow in cell culture [70], thus, many studies are 
conducted with type II because it can be grown in vitro. The cellular receptor for type II FCoV is 
feline aminopeptidase N (fAPN or CD13) [71], but the cellular receptor for type I has not yet 
been identified [72]. Feline cell-specific intracellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN) is reported to enhance entry of FCoV type II [73, 74].  
 
FCoVs are also divided into two biotypes, feline enteric coronavirus (FECVs) and feline infec-
tious peritonitis virus (FIPV), based on the clinical outcome. FCoV that causes inapparent or 
mild to severe enteritis is called FECV. FECV transmits via oral-fecal route [75, 76] and is ubiq-
uitous in multi-cat households and catteries. This virus infects enterocytes in the intestines [70, 
77, 78], causing villous atrophy in severe cases [79, 80]. FECV infections are rarely fatal and 
most cats recover without complications. However, some cats shed viruses persistently or inter-
mittently for several months to years [76, 80]. Re-infections are possible with the same or a dif-
ferent strain of FECV [76, 81].  
 
A small fraction of cats (less than 5%)  develop feline infectious peritonitis (FIP) that is a fatal, 
systemic disease [82]. FIP occurs most frequently in cats of 6 months to 2 years of age [83-88]. 
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Direct transmission of FIPV between cats is rare [83, 86, 89-91]. Higher incidences of FIP is as-
sociated with some cat breeds, such as Abyssinians, Bengals, Birmans, Himalayans, Ragdolls 
and Rexes, and certain blood-lines, suggesting genetic influence on FIP development [88, 92, 
93]. Increased risk of FIP is also reported in sexually intact males [94], catteries or multi cat 
households, stress or co-infections with feline leukemia virus or feline immunodeficiency virus 
[95, 96].   
 
There are two forms of FIP: wet/effusive form and dry/non-effusive form. Dry form shows no or 
little effusion in the body cavities but may develop effusion with disease progression. Wet form 
is characterized by the presence of chest or abdominal effusions rich in protein and fibrin. Granu-
lomatous vasculitis and granulomas are characteristic lesions of FIP, and occur in various organs 
including kidneys, liver and central nervous system (CNS). These lesions are composed of mac-
rophages, neutrophils, lymphocytes and plasma cells [97-101]. FIPVs infect and efficiently repli-
cate in macrophages [102, 103]. This shift in cell tropism from enterocytes to macrophages is 
considered the major event for virulent systemic infection [98]. Host immunity also plays an im-
portant role in the development of FIP. Dry FIP is associated with partial response of host cellu-
lar immunity and effusive FIP is thought to be associated with the lack of vigorous cellular im-
munity [98]. Humoral immunity is not protective and it may enhance disease progression due to 
antibody dependent enhancement (ADE) of FIP [96, 104-109]. 
 
Two theories have been suggested on the occurrence of FIPV. Brown et al. [110] proposed that 
there are separate FIPV and FECV strains circulating in feline populations. However, the widely 
accepted theory is the internal mutation theory, which suggests that FIPV arises from viral muta-
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tions in individual cats infected with FECV, enabling the virus to efficiently replicate in macro-
phages [86, 90, 96, 111-113].  
 
Previous studies have suggested that accessory proteins 3c, 7b and S protein may play important 
roles in FIPV development. It was reported that truncated 3c protein is frequently associated with 
FIPV, while intact 3c protein is found in most FECVs [83, 86, 111, 114-116]. Thus, it has been 
suggested that either the intact 3c protein is important for virus replication in intestinal epithelial 
cells or truncated 3c protein may facilitate efficient viral replication in macrophages [86, 89]. In 
vitro studies have shown that an intact ORF7 is important for FIPV replication in macrophages 
[117]. In addition, deletions in 7b gene identified in cell culture passaged FIPV strains were as-
sociated with loss of virulence and attenuation in vivo [118]. However, sequence analysis of 
FCoV field isolates has shown that most isolates had intact 7b genes and deletions in 7b gene can 
be present in both FECVs and FIPVs [116, 119]. Therefore, deletions in 7b gene might be asso-
ciated with loss of virulence and attenuation in vivo but not with transformation of FECV to 
FIPV [98, 111]. Mutations and deletions have also been identified in the S gene of FIPVs [111, 
120] at S2 region [89, 121] and S1/S2 or S2’ cleavage sites [91, 122] which could be contrib-
uting to virulent pathogenicity or tropism change. 
 
1.5.1 Current preventive and therapeutic measures for FIP 
 
Felocell FIP (Zoetis US) is the only commercially available vaccine for FIP. It contains a cell 
culture passaged, attenuated, temperature sensitive FCoV strain (DF2) and is licensed for cats at 
16 weeks or older. However, the efficacy of the vaccine is low in cats with prior FCoV infections 
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which are common in FCoV endemic environments [100, 123], and kittens in these FCoV en-
demic environments can become seropositive before the age of 16 weeks. Currently this vaccine 
is not recommended by the American Association of Feline Practitioners (AAFP).  
 
Despite the gravity of the disease, currently available treatment options for FIP are limited. Im-
mune-suppressive drugs such as prednisolone are commonly used to alleviate clinical signs of 
FIP [97]. Immunostimulants such as polyprenyl immunostimulants (PI) have been studied for 
prolonging survival time and increasing quality of life of cats with dry FIP [124, 125]. Admin-
istration of recombinant human interferon alpha in combination with Propionibacterium acnes to 
experimentally FIPV infected cats has shown increased survival time [126]. Treating FIP cats 
with recombinant feline interferon also increased the survival of several cats, although the study 
lacked a control group to establish the findings [127]. However, a controlled study with FIP cats 
showed no significant difference in the survival time between the cats treated with feline inter-
feron-omega or a placebo [128]. Administration of choloroquine has shown inhibitory effects on 
FIPV replication in cell culture and anti-inflammatory effects in experimentally infected cats 
[129]. Diphyllin [130] and cyclosporin A [131, 132] were reported to inhibit the replication of 
FIPV in cell culture. 
 
Many direct acting antivirals have also been tested to determine effectiveness of inhibiting FIPV 
replication. Small interfering RNA (siRNA) [133], nucleoside analogs [134, 135], HIV protease 
inhibitor nelfinavir [136], carbohydrate binding agents [136], synthetic peptides that interfere 
with membrane fusion [137] and 3CLpro inhibitors [138-142] have been tested for FIPV, mostly  
in cell culture and several in vivo.  
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1.6 Ferret and mink coronaviruses  
 
FRCoV belongs to alphacoronaviruses [143-146] and clusters in the mustelid alphacoronavirus 
clade with MCoVs [147]. FRCoV infections in ferrets (Musela putorius furo) may cause two dis-
tinct clinical diseases: epizootic catarrhal enteritis (ECE) [148, 149] or a FIP-like systemic dis-
ease known as ferret systemic virulent coronavirus (FRSCV) infection [144, 150, 151].  
 
ECE was first described in the US in the early 1990s [148] and many cases have subsequently 
been reported in several countries [149, 152]. ECE is an enteric disease and is also known as the 
‘green slime disease’. The clinical signs of ECE include lethargy and anorexia followed by pro-
fuse ‘greenish, foul smelling’ diarrhea that can progress into a chronic stage where feces resem-
ble small grainy material [100, 153]. ECE is highly contagious affecting ferrets of any age group 
and the clinical signs tend to be severe in older animals [148, 153]. FRCoV that causes ECE is 
designated as ferret enteric coronavirus (FRECV) [152]. FRECV causes enteritis by infecting 
villar epithelial cells in the jejunum and colon and transmits via fecal-oral route [148]. Therefore, 
preventive measures such as cleaning litter boxes and minimizing transmission through fomites 
can help prevent the spread of the disease where multiple ferrets are housed together [148, 151]. 
 
FRSCV was first described in the early 2000s in the US [150] and Spain [143] with subsequent 
reports from many countries [145, 150, 152, 154-157]. The genomes of FRSCV and FRECV are 
genetically similar [150, 158], and it is suggested that FRSCV arises by de novo mutations in 
FRECV-infected ferrets, as speculated for FIPV [150, 158]. The clinical signs of FRSCV infec-
tion in ferrets resemble those observed in cats with FIP and include diarrhea, lethargy, weight 
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loss, coughing, sneezing, dyspnea, jaundice, skin erythema, and ‘greenish’ urine [150]. Pyogran-
ulomatous lesions are commonly found in multiple organs such as the spleen, mesenteric lymph 
nodes, intestines, kidneys and CNS [150, 151, 153, 156, 159] while effusions are noted in infect-
ed ferrets only occasionally [150, 153, 157]. FRSCV infection is fatal and occurs often in young 
animals [150]. 
 
MCoVs, an alphacoronavirus [147, 160], infect minks. Minks are carnivores that are closely re-
lated to ferrets and mostly valued for their fur. There are two species of minks that are classified 
into different genera: larger American mink (Mustela lutreola) and smaller European mink (Neo-
vison vison). European mink is a critically endangered species. MCoV is the causative agent of 
mink ECE, which was first reported in 1975 [161, 162]. Mink ECE resembles ECE in ferrets 
[149] and infected minks develop mucoid diarrhea and anorexia [163]. Mink ECE affects young-
er (especially during parturition to weaning) and older minks, and dark colored minks have a ge-
netic predisposition for MCoV infection [163]. Seasonal (higher incidences in early fall) fluctua-
tions in the incidence of ECE has also been noticed [163]. Mink ECE is highly infectious (100%) 
but rarely fatal (<5%) and mortality is usually associated with co-morbidities such as Aleutian 
disease [163]. The major economic consequence of ECE is the decreased pelt quality [163]. Sys-
temic MCoV disease has not been reported in minks so far.  
 
No vaccine or treatment exists for FRCoV or MCoV infections other than supportive care [151, 
153, 160]. Culture of ferret and mink coronaviruses is fastidious, thus, research on disease path-
ogenesis and development of therapeutics for FRCoV or MCoV is difficult [148-150, 160].  
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1.6.1 Potential therapeutic targets for coronavirus infections 
 
Host factors that are exploited in coronavirus replication have been utilized as a target for de-
signing therapeutics for coronavirus infections. Host receptors important for virus attachment 
and entry can be targeted by monoclonal antibodies or inhibitors [164]. Inhibitory agents of host 
cellular proteases can block the proteolytic cleavage of viral spike protein [165-167]. Enhancing 
host interferon response against coronavirus infection is another strategy that has been tested for 
SARS-CoV and MERS-CoV in vitro [168-171].  
 
Coronavirus proteins are also targeted to develop antiviral drugs for coronavirus infections. 
Monoclonal antibodies that target viral S protein [172-178], inhibitors that block the formation of 
RTC such as K22 [179], drugs that inhibit viral nucleic acid synthesis such as commercially 
available mycophenolate mofetil [180] or ribavirin in combination with interferon [181-183], 
virus helicase inhibitors such as SSYA10-001 [184], nucleoside analogs such as GS-5734 [185] 
and siRNAs targeting expression of the viral structural genes [186, 187] target coronavirus pro-
teins. Among the viral proteins that are targeted for therapeutic purposes, coronavirus protease 
inhibitors, PLpro inhibitors [188-191] and 3CLpro inhibitors have been researched. Further de-
tails on inhibitors targeting 3CLpro are described in the following section. 
 
1.7 Inhibitors of coronavirus 3CLpro 
 
Small molecules such as metal conjugates [192-195], isatin derivatives [196-198], pyrimidines 
[199], keto-glutamine analogues [200], decahydroisoquinolin [201], boronic acid compounds 
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[202], phenyl esters [203], trifluoromethyl ketones [204], chloromethyl ketones [52], α-β-
unsaturated ketones, esters, and amides, N-substituted maleimides, sulfur and nitrogen contain-
ing compounds [205] have been reported for their antiviral effects against SARS-CoV 3CLpro. 
In addition, antiviral effects of natural compounds such as theaflavin-3,3'-digallate (TF3) in 
black tea [206], I. indigotica root extracts [207], chalcones from Angelica keiskei root extract 
[208], phytocompounds including diterpenes, triterpenes, liganoids and curcumin [209] have also 
been reported for SARS-CoV. However, many of these compounds have not been tested for their 
in vivo efficacy.  
 
Petidomimetic 3CLpro inhibitors mainly target the active center of 3CLpro although dimeric in-
terface of 3CLpro can also be targeted [60]. One group studied the effectiveness of an N-terminal 
octapeptide molecule targeting dimeric interface of SARS CoV as a dimerization inhibitor [210]. 
Peptidomimetic inhibitors that target the active center resemble the natural polypeptide substrate 
of coronavirus 3CLpro and interact with the catalytic Cys residue of 3CLpro. Many studies have 
utilized peptidomimetic inhibitors to gain insight on key interactions between the inhibitor and 
3CLpro for the development of 3CLpro inhibitors [48, 54, 55, 211, 212]. 3CLpro inhibitors for 
SARS-CoV and MERS-CoV have been the focus of many studies [212-219]. Development of 
3CLpro inhibitors utilizing structure based design has been reported previously by our group for 
a range of coronavirus infections including FIPV [139-141, 218-222]. Recently, the efficacy of 




1.8 Antiviral resistance 
 
RNA viruses can evolve rapidly due to the lack of intrinsic proof reading activity of the virus 
replicase protein during viral replication, which results in genetic variants (quasi species) in a 
single host [223, 224]. Selective pressure such as antiviral treatment can confer a selective ad-
vantage on existing resistant variants to replicate in the presence of the drug (pre-existing drug 
resistance) or can drive the generation of new resistant variants in the population as a result of 
adaptation and evolution (acquired drug resistance). The replication efficiency of these variants 
may change or be the same as the wild type. The variants with higher replication efficiency or 
higher fitness can establish in the population causing decreased susceptibility to drugs [225, 
226]. Ease of generating critical mutations by the virus to acquire resistance [227, 228] and fit-
ness of resistant virus variants as well as host dependent conditions such as immune status of the 
host and non-adherence to antiviral treatment regimen or prolonged antiviral treatment are im-
portant factors in the development of antiviral resistance [226, 229]. Antiviral drugs with differ-
ent mechanisms of actions administered in combination may reduce the emergence of antiviral 
resistance [227, 228, 230, 231]. One instance is the common antiretroviral therapy for HIV re-
ferred to as highly active antiretroviral therapy (HAART), which is a combination of at least 
three HIV inhibitors [229].  
 
There are limited studies on antiviral resistance of coronaviruses. Antiviral resistance to carbo-
hydrate-binding plant lectins due to substitutions in the S genes of MHV and FIPV were ob-
served in cell culture [232]. MHV rapidly generated resistance to 3CLpro inhibitor GRL-001 
within four cell culture passages. Single (T26I or D65G) and double (T26I/D65G, T26I/D65A, 
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or T26I/A298D) amino acid changes in these resistant MHV variants were identified [233]. T26I 
and D65A/G were in domain I, where T26I was close to the active center, and A298D was in 
domain III of 3CLpro [233]. The resistant MHV variants with a single amino acid change (T26I 
or D65G) showed ̴ 3 fold increase in 50% effective concentration (EC50) in comparison to the 
wild-type. The resistant MHV variants with double amino acid changes (T26I/D65G and 
T26I/A298D) showed even greater resistance (more than 6 fold increase in EC50) than those with 
a single amino acid change [233]. But, T26I/D65G resistant MHV variants displayed delayed 
replication in vitro and attenuation in vivo [233]. FIPV also generated resistance for 3CLpro in-
hibitor NPI52 before 10 passages in cell culture [138]. At passage 10, the EC50 of NPI52 in-
creased by 15 folds and the resistant variants had S131C which was located in domain II of 
3CLpro [138]. However, FIPV did not generate resistance for 3CLpro inhibitor GC376 even af-
ter 20 passages in cell culture [138]. These studies show that generation of antiviral resistance 
depends on the inhibitory compound. Generation of antiviral resistance against 3CLpro inhibitors 















Feline coronavirus (FCoV) is a common pathogen that causes enteritis in cats. However, feline 
infectious peritonitis (FIP) may develop in some cats following FCoV infection. Ferret corona-
virus (FRCoV) can cause epizootic catarrhal enteritis or a fatal systemic disease with clinical 
signs similar to that of in enteritis or FIP in cats, respectively. Mink coronavirus (MCoV) infects 
minks and can cause epizootic catarrhal enteritis resulting in detrimental body conditions that 
leads to economic loss in fur farms. However, there are no effective preventive or therapeutic 
methods for these infections and no antivirals have yet been reported for FRCoV or MCoV up to 
now. We have previously generated 3CLpro inhibitors of FCoV and reported the efficacy of a 
3CLpro inhibitor in cats with FIP. We conducted a structure-function study of 3CLpro inhibitors 
and their activities against FCoV, FRCoV and MCoV 3CLpro using fluorescence resonance en-
ergy transfer (FRET) assay and identified potent 3CLpro inhibitors for these coronavirus 
3CLpros. We also constructed the 3D homology structures of FRCoV and MCoV 3CLpros and 








2.2 Introduction  
 
Coronaviruses are enveloped viruses that contain a positive sense, single stranded RNA genome. 
Coronaviruses infect a wide range of animal species including humans [12]. Coronaviruses be-
long to the Coronaviridae family, which is subclassified into alpha, beta, delta and gamma coro-
naviruses [4]. Alphacoronaviruses infect humans as well as animals and include HCoV-229E and 
HCoV-NL63 that cause common cold in humans, porcine epidemic diarrhea virus (PEDV), 
transmissible gastroenteritis virus (TGEV), canine coronavirus (CCoV), feline coronavirus 
(FCoV), ferret coronavirus (FRCoV) and mink coronavirus (MCoV) [4]. FCoV infects the mem-
bers of the Felidae family including domestic and wild cats and is a common cause of mild en-
teritis [75, 234]. However, a 100% fatal, systemic disease known as feline infectious peritonitis 
(FIP) may occur [96, 235] in less than 5% of FCoV infected cats [82, 96]. There are two clinical 
forms of FIP, wet/effusive form and dry/non-effusive form. Pleural or abdominal effusions are 
characteristic of wet FIP while absence of effusion or mild effusion is typical of dry FIP [97-
100]. Granulomatous inflammatory lesions also appear in various organs including eyes, liver, 
kidneys and central nervous system in cats with FIP [96, 236].  
 
Ferrets are popular pets especially in the USA and are also bred for fur. A new diarrheal disease 
was first reported in pet ferrets and ferrets from fur farms in 1993 from the east coast of USA 
[148] with subsequent reports from around the world. FRCoV causes epizootic catarrhal enteritis 
(ECE) affecting ferrets of any age group but the clinical signs tends to be severe in older ferrets 
[148]. Ferrets with ECE display clinical signs including foul smelling, green, mucous-laden diar-
rhea, vomiting, anorexia and lethargy [148]. Despite close to 100% morbidity, the fatality rate of 
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ECE is <5% [148]. In 2002, a systemic disease was reported in ferrets that were infected with 
FRCoV in the Europe and the USA, and the disease was named as ferret systemic coronavirus 
(FRSCV) associated disease [150]. FRSCV infection resembles FIP in clinical signs and system-
ic pyogranulomatous inflammation [150, 151, 157]. Similar to FIP, this disease is fatal and 
young animals are more susceptible than older animals [150].  
 
Minks are close relatives of ferrets and farmed for fur. MCoV infection causes ECE in minks, 
which was first reported in 1990 [163]. Mink ECE is associated with anorexia leading to lower 
body conditions, which is particularly of concern in fur industry [160, 162, 163]. However, fatal 
systemic virulent coronavirus infection resembling FIP or FRSCV has not been reported in 
minks so far. ECE in minks is highly infectious but rarely fatal unless the animal has concurrent 
Aleutian disease, an enteric parvovirus infection [163].  
 
Despite the importance of coronavirus infections in these animals, there are no effective preven-
tive or treatment options. This reiterates the need to develop preventive or therapeutic strategies 
for these viral diseases. Coronaviruses produce viral polyproteins during virus replication, which 
are to be cleaved into mature virus proteins. The cleavage of viral polyproteins is conducted by 
virus-encoded papain-like proteases and 3C-like protease (3CLpro). The 3CLpro processes the 
majority of cleavage sites on virus polyproteins and is essential for virus replication. Our lab has 
previously demonstrated the antiviral effects of 3CLpro inhibitors of coronaviruses, including 
FCoV, in vitro and in vivo [138-142].  
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3CLpro inhibitors against FCoV have been previously reported by us and the efficacy of a 
3CLpro inhibitor was successfully demonstrated in cats with FIP. Therefore, in this study, we 
evaluated a library of previously reported and newly synthesized 3CLpro inhibitors and identi-
fied 3CLpro inhibitors against FRCoV or MCoV in fluorescence resonance energy transfer 
(FRET) assay and investigated the structure-function relationship of these inhibitors. We also 
investigated the structural homology among FIPV 3CLpro crystal structure and 3D models of 
FRCoV and MCoV 3CLpros.  
 
2.3 Materials and Methods  
 
2.3.1 3CLpro inhibitors 
 
Synthesis of NPI52 [218], GC376 [140], GC551 and GC543 [222], GC523 [221], GC583, 
GC587, GC591 and GC597 [237] were previously reported by our group. GC772 and GC774 
were synthesized in the laboratory of W. C. Groutas (Department of Chemistry, Wichita State 
University).  
 
2.3.2 Cells and viruses 
 
Crandell-Rees Feline Kidney (CRFK) Cells and FIPV WSU-79-1146 strain were obtained from 
ATCC (Manassas, VA). CRFK cells were maintained in Minimal Essential Medium (MEM) 
with 5-10% fetal bovine serum, penicillin (250U/ml) and streptomycin (250ug/ml). FIPV WSU-
79-1146 strain was propagated in CRFK cells.  
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2.3.3 Multiple amino acid sequence alignment of 3CLpros of FCoVs, FRCoVs and 
MCoVs  
 
Multiple amino acid sequence alignment of 3CLpros of 40 FCoV strains, five FRCoV strains 
(GenBank accession numbers KM347965, LC215871, LC119077, KX512809, KX512810) and 
three MCoV strains [WD1133, WD1127 and MCoV China (Genbank accession numbers 
HM245926, HM245926 and MF113046, respectively)] were constructed using Clustal Omega 
multiple sequence alignment program (https://www.ebi.ac.uk/). The 3CLpro amino acid se-
quence of TGEV Miller strain (Genbank accession number DQ811786) was used as a reference.  
 
The FRCoV strains KX512809 and KX512810 were from Michigan, USA, FRCoV4370 and fer-
ret063 (Genbank accession numbers LC119077 and LC215871, respectively) were from Japan 
while NL-2010 (Genbank accession number KM347965) was from the Netherlands. The two 
MCoV strains were from two independent outbreaks in farms in the USA (WD1127 from Wis-
consin and WD1133 from Minnesota in 1998) and one MCoV was from China. 
 
2.3.4 Expression and purification of recombinant 3CLpro  
 
Codon optimized cDNA encoding 3CLpros of FRCoV strain NL-2010 (Genbank accession 
number KM347965) and MCoV strain WD1133 (Genbank accession number HM245926) were 
synthesized by GenScript (Piscataway, NJ). These cDNA sequences were cloned into pET-
28a(+) vector (GenScript, Piscataway, NJ), which was then transformed into Escherichia Coli 
24 
BL21 cells (Invitrogen, Waltham, MA). Expression of 3CLpro was induced by 1mM isopropyl 
β-D-thiogalactopyranoside (IPTG) in Luria Bertani broth medium for 4-6 hrs at 37 °C in a shak-
ing incubator. The cells were harvested at the end of induction by centrifugation and the 3CLpros 
were purified using a Ni-NTA affinity column (QIAGEN, Valencia, CA). The purified 3CLpros 
were stored at -80 °C until use. Expression of 3CLpro of FIPV-m3c-2 was previously described 
[138]. 
 
2.3.5 FRET protease assay 
 
FRET assay buffer comprised of 120mM NaCl, 4mM DTT, 50mM HEPES, 30% Glycerol at pH 
6.0 was used for the assay. Serial dilutions of each 3CLpro were prepared in assay buffer and 
each dilution was added to Corning™ Falcon™ 96-well imaging microplate containing 25µl of 
substrate (5-FAMSAVLQSGK(QXL520)NH2) and the mixture was incubated at 37 ˚C for up to 
90 min. Fluorescence readings were measured using a fluorescence microplate reader (FLx800, 
Biotek, Winooski, VT) at excitation and emission wavelengths of 485 and 516 nm, respectively. 
Fluorescence readings were measured at 10 min, 20 min, 30 min, 60 min and 90min. The back-
ground fluorescence (reading from substrate only well) was subtracted from each reading. 
 
Next, the activity of inhibitors against each 3CLpro was assessed. The 10mM stock solutions and 
serial dilutions of the inhibitors were made in Dimethyl Sulfoxide (DMSO). Then, each dilution 
of the inhibitor was added to assay buffer containing 3CLpro and the mixture, with a total vol-
ume of 25 µl was incubated at 37 °C for 30 min. Following the incubation, the mixture was add-
ed to Corning™ Falcon™ 96-well imaging microplate containing substrate in 25µl of assay 
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buffer. This mixture was further incubated at 37 °C for 30 min and fluorescence values were 
measured after incubation. Relative fluorescence units were calculated by subtracting the back-
ground fluorescence. The 50% inhibitory concentration (IC50) of each inhibitor was calculated by 
using non-linear regression (four parameter variable slope) using GraphPad Prism software ver-
sion 6 (GraphPad, La Jolla, CA).  
 
2.3.6 3D structural models of FIPV, FRCoV and MCoV 3CLpros 
 
Homologous 3D structure models of 3CLpros of FRCoV strain NL-2010 and MCoV strain 
WD1133 were generated by using I-TASSER protein 3D structure prediction tool [238, 239] and 
3CLpro crystal structures of FIPV (PDB accessions 4ZRO and 5EU8), PEDV (PDB accession 
4XFQ), bat coronavirus HKU4 (PDB accession 2YNA), TGEV (PDB accession ILVO), SARS 
coronavirus (PDB accession 5B60) and human coronavirus 229E (PDB accession 2ZU2) as tem-
plates. The generated structures were analyzed in PyMol [240] and superimposed with the 
3CLpro crystal structures of FIPV or TGEV (PDB accession 4F49) for in-silico visualization of 
the structural homology between the 3CLpros.  
 
2.3.7 Cytotoxicity assay 
 
The cytotoxic effects of the inhibitors were assessed by incubating various concentrations of the 
inhibitors (up to 150 µM) for 36 hours in CRFK cells seeded in 96 well plates. Cytotoxicity of 
the inhibitors was measured using the CytoTox96 nonradioactive cytotoxicity assay kit 
(Promega, Madison, WI) according to the manufacturer’s instructions. The 50% cytotoxic con-
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centration (CC50) of each inhibitor was determined with non-linear regression using GraphPad 
Prism software version 6 (GraphPad, La Jolla, CA). 
 
2.3.8 Antiviral effects of the inhibitors in cell culture against FIPV 
 
Since FRCoVs and MCoVs do not grow in cell culture, we tested the inhibitors against FIPV 
strain WSU-1146 that grows well in cell culture. Stock solutions of each inhibitor were prepared 
in DMSO at 10 mM and serial dilutions of each inhibitor were prepared in MEM. These dilu-
tions of inhibitors were added to confluent monolayers of CRFK cells in 12 or 24 well plates. 
Mock treated wells with only media were used as a control. The cells were then immediately in-
fected with FIPV strain WSU-1146 at an MOI of 0.05-0.1. Then the plates were incubated at 37 
°C until cytopathic effects were observed, at which time the plates were frozen. The virus titers 
were determined by tissue culture infectious dose 50 method (TCID50) [241] and the 50% effec-
tive concentration (EC50) for each inhibitor was calculated with non-linear regression using 
GraphPad Prism software version 6 (GraphPad, La Jolla, CA). 
 
2.4 Results  
 
2.4.1 Multiple amino acid sequence alignment of 3CLpros of FCoVs, FRCoVs and 
MCoVs 
  
Multiple amino acid sequence alignment showed that the FRCoV strains share a 3CLpro amino 
acid sequence homology of 97.02-100% despite the different geographical locations they were 
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from. The MCoV strains share a 97.66-98.68% 3CLpro amino acid sequence homology. FRCoV 
and MCoV 3CLpro amino acid sequences share a homology of 83.44-85.95%. The 3CLpro ami-
no acid sequences of 40 FCoV strains whose sequences are available in Genbank have a homol-
ogy of 95.03-100%. FRCoV and MCoV 3CLpro amino acid sequences share 74.17-78.15% and 
71.52-73.58% homologies with FCoV 3CLpro amino acid sequences, respectively.  
 
The 3CLpro amino acid sequence of TGEV Miller strain was included in the analysis because 
our lab has previously reported that GC376 is a potent 3CLpro inhibitor of TGEV as well as 
FIPV. The crystal structure of TGEV 3CLpro bound with GC376 was also reported by our group 
[140]. TGEV Miller strain 3CLpro amino acid sequence shares a homology of 92.05-93.71% 
with FCoV 3CLpro amino acid sequences, and TGEV 3CLpro crystal structure (PDB accession 
4f49) shows a high structural homology with the available FCoV 3CLpro crystal structures (PDB 
accessions 4ZRO and 5EU8). His41 and Cys144 catalytic dyad is conserved at the active site of 
3CLpros of TGEV, FCoV, FRCoV and MCoVs (Fig. 2-1). GC376 interacts with Thr47, Phe139, 
Cys144, His162, His163 and Glu165 in TGEV 3CLpro [140]. Analysis of the 3CLpro amino ac-
id sequences of FCoV, FRCoV and MCoVs revealed that the residues involved with GC376-






Figure 2-1: Multiple amino acid sequence alignment of FCoV, FRCoV, MCoVs and TGEV 
3CLpros 
In this alignment, two FCoV strains are shown. The catalytic residues H41 and C144 and resi-
dues that forms bonds with GC376 (T47, F139, C144, H162, H163 and E165) in TGEV 3CLpro-
GC376 complex [140] are indicated with numbers.  
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2.4.2 FRET assay of the 3CLpro inhibitors against recombinant 3CLpros of FIPV, 
FRCoV and MCoVs 
 
The activity of the 3CLpros of FRCoV and MCoV was determined prior to the inhibition assay. 
The fluorescence signals from both proteases increased with time following a similar trend as 




Figure 2-2: The activity of recombinant 3CLpros of FIPV, FRCoV and MCoV in the ab-
sence of an inhibitor 
The 3CLpros were incubated with the substrate in assay buffer and fluorescence readings were 
measured. The activity of each 3CLpro is indicated as a percentage at each time point. An en-
zyme activity of 100% is indicated when all the substrate molecules are processed by 3CLpro. 
Each bar represents the mean ± standard error of means (SEM) of enzyme activity at each time 






























Next, the activities of inhibitors with different R groups were assessed for 3CLpros of FRCoV 
and MCoV as well as FIPV 3CLpro. Chemical structures of the inhibitors and their IC50 values 
are summarized in Table 2-1.   
 
GC376 is a potent 3CLpro inhibitor for FIPV [138, 142]. Thus, we included GC376 as a refer-
ence in this study. GC376 showed slightly lower activity against FRCoV and MCoV 3CLpros in 
comparison to that against FIPV 3CLpro (Table 2-1).  
 
We have previously reported that bisulfite-adduct warhead (at R4 in Table 2-1) is converted to 
the aldehyde form, and both aldehydes and their bisulfite adducts show similar activity [140, 
141, 222]. GC543 and GC583 are the aldehyde forms of GC551 and GC587, respectively, and 
similar inhibitory effects were observed between these aldehyde and bisulfite-adduct pairs, 
which is in line with the previous report by our group.  
 
Replacement of bisulfite adduct at R4 in GC376 with a ketoamide [-C(O)C(O)NH-(Cyc-Hexyl)] 
in GC523 showed slightly decreased activity against FIPV 3CLpro with no considerable changes 
against FRCoV and MCoV 3CLpros, in comparison to that of GC376. GC591, GC587 and 
GC583 have the same structure except at R4, where they have ketoamide [-C(O)C(O)NH-(Cyc-
Propyl)], bisulfite adduct and CHO, respectively. GC591 showed a marked decrease in the ac-
tivity against FIPV 3CLpro compared to GC587 and GC583 and the decrease of activity was 
more pronounced against FRCoV and MCoV 3CLpros. 
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With reference to the structure of GC376, substituting Leu for Cha group at R3 (as in GC551) 
did not markedly affect the activity against all three 3CLpros. The structure of GC583 and 
GC597 are the same except GC583 has a Cha group at R3 while GC597 has a Leu group. The 
activities of GC583 and GC597 were similar to each other against all three 3CLpros. This sug-
gests that Cha or Leu at R3 do not markedly affect the activity against all three 3CLpros.  
 
GC543 and GC583 have the same structure except at R1 where GC543 has a benzyl group and 
GC583 has a m-Cl benzyl group. Both GC543 and GC583 showed similar activity against all 
three 3CLpros. GC551 and GC587 also differ only at R1 where GC551 has a benzyl group and 
GC587 has a m-Cl benzyl group. GC551 and GC587 showed slightly increased activity against 
all three 3CLpros. These results suggest that inhibitors with a benzyl or m-Cl benzyl groups at 
R1 and bisulfite adduct at R4 have most potent activity against all three 3CLpros.  
 
The inhibitors with a carboxyl group at R2 showed submicromolar IC50s for all three 3CLpros 
except GC591. In contrast to all the other inhibitors with a carboxyl group at R2 (see Table 2-1), 
GC772 and GC774 have sulfonyl groups at R2. Both GC772 and GC774 showed marked de-
crease in the activities for all three 3CLpros. Furthermore, comparison of the activities of GC583 
and GC772 reveals that a sulfonyl group at R2 greatly reduced the activity against all three 
3CLpros. When compared to the activity of GC772, the presence of a para-chlorobenzene group 
at R1 in GC774 further decreased the activity against 3CLpros of FRCoV and MCoV without 
affecting the activity against FIPV 3CLpro.  
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In summary, all tested dipeptidyl inhibitors except GC591, GC772 and GC774 had submicromo-
lar IC50 values for FIPV, FRCoV and MCoV 3CLpros in FRET assay. The most potent dipep-
tidyl inhibitor among the tested inhibitors was GC587 with IC50 values of 0.15 µM for FIPV 
3CLpro, 0.29 µM for ferret 3CLpro and 0.59 µM for mink 3CLpro (Table 2-1).  
 
NPI52 is a tripeptidyl inhibitor which has an aldehyde warhead at R4 and an additional 1-
napththylalanine moiety at the position corresponding to P3, in comparison to the structure of 
GC376 [139]. NPI52 showed increased effectiveness against all three 3CLpros and the activity 
















Table 2-1: Structures and the inhibitory activities of the inhibitors for FIPV, FRCoV and 
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GC551 Benzyl Carboxyl 
 







GC583 m-Chloro Benzyl Carboxyl 
 






GC587 m-Chloro Benzyl Carboxyl 
 


















































0.22±0.03 0.14±0.03 0.26±0.16 
 
The IC50 is the mean ± standard error of the means (SEM) of 50% inhibitory concentrations 
(IC50s) from at least three independent FRET assays.  
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2.4.3 3D structures of 3CLpro of FIPV, FRCoV and MCoV 
 
We constructed 3D homology models of 3CLpros of FRCoV and MCoV using the ITASSER 
online 3D structure prediction tool [242] to investigate the structural homology. The predicted 
homology models of these two 3CLpros showed a confidence score of 2, estimated TM score of 
0.99±0.04 and root-mean-square deviation (RMSD) of 2.3±1.8Å (for both), indicating that these 
structure models are reliable.  
 
The crystal structure of TGEV 3CLpro (PDB accession 4F49) was superimposed with crystal 
structure of FIPV 3CLpro (PDB accession 4ZRO) to determine the structural similarity between 
these 3CLpros. The overall distance was 0.975 Å (Fig. 2-3) and the distance between 125 super-
imposed Cα atoms (residues 41-165 which contains catalytic residues and GC376-interacting 
residues) of TGEV and FIPV 3CLpros was 0.415 Å. This indicates the high structural homology 
between TGEV and FIPV 3CLpros. 
 
The distance between the superimposed crystal structure of TGEV 3CLpro and homology model 
of FRCoV 3CLpro was 0.652 Å for all atoms or 0.559 Å for 125 Cα atoms (residues 41-165). 
The distance between the crystal structures of TGEV 3CLpro and homology model of MCoV 
3CLpro was 0.648 Å for all atoms or 0.547 Å for 125 superimposed Cα atoms (residues 41-165). 
Superimposition of the crystal structure of FIPV 3CLpro (PDB accessions 4ZRO) with the ho-
mology models of FRCoV and MCoV 3CLpros showed distances of 0.674 and 0.672 Å for all 
atoms, respectively (Fig. 2-4). The superimposed 125 Cα atoms (residues 41-165) of FIPV 
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3CLpro with those of FRCoV and MCoV 3CLpros showed distances of 0.441 and 0.418 Å, re-
spectively. These RMSD values indicate that the homology models of FRCoV and MCoV 
3CLpros are highly homologous to the crystal structures of TGEV and FIPV 3CLpros. The over-
all distance between the superimposed homology models of FRCoV and MCoV 3CLpros was 
0.225 Å and the distance between superimposed 125 Cα atoms (residues 41-165) showed a dis-
tance of 0.268 Å. Thus, the overall structures of 3CLpros appear to be well conserved among 
these coronaviruses and FRCoV and MCoV 3CLpro structure models are closely related to each 
other than to that of FIPV and TGEV 3CLpro crystal structures. The active site of the superim-
posed FIPV 3CLpro and homology 3CLpro models of FRCoV and MCoV is shown in figure 2-











The crystal structures of TGEV 3CLpro and FIPV 3CLpro were superimposed to show their 
structural similarities. The cartoon representation of the crystal structure of TGEV 3CLpro (PDB 
accession 4F49) and FIPV (PDB accession 4ZRO) are indicated in grey and light blue, respec-
tively. The 3CLpro monomer of coronaviruses consists of three domains; domain I, II and III 
with the active site located between domains I and II [48, 55]. The catalytic residues (His41 and 
Cys144) of both 3CLpros are indicated in red. GC376 is shown in blue.  
 
 
Figure 2-3: Superimposed crystal structures of TGEV and FIPV 3CLpros 
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The cartoon representations of the 3D 3CLpro structures of FRCoV (blue), MCoV (purple) and 
the crystal structure of FIPV 3CLpro (PDB accession 4ZRO in cyan) are superimposed to indi-







Domain III   Domain II   Domain I 
Figure 2-4: Superimposition of 3D homology models of FRCoV and MCoV 3CLpros and 






GC376 is shown as a red stick. Catalytic residues (H41, C144) and residues that interact with 
GC376 (T47, F139, C144, H162, H163, E165) in TGEV 3CLpro-GC376 complex are labeled. 




Figure 2-5: Enlarged active site of the superimposed FIPV 3CLpro crystal structure 
and 3D homology models of FRCoV and MCoV 3CLpros 
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2.4.4 Antiviral effects of the inhibitors on the replication of FIPV in cell culture 
 
The antiviral effects of GC376, GC551 and GC543 against FIPV have been previously reported 
by our group [141]. However the rest of the inhibitors have not been reported for FIPV. None of 
the inhibitors have been reported for FRCoV or MCoV. The 50% cytotoxicity concentrations of 
the dipeptidyl inhibitors were higher than 100 or 150 µM (Table 2-2). NPI52 showed 50% cyto-
toxicity at 70.29 ± 5.6 µM. The EC50 values of all the inhibitors ranged from 0.02 to 0.55 µM 
(Table 2-2). These EC50 values are in line with the IC50 values determined in the FRET assay. 












Figure 2-6: Dose dependent inhibitory curve of a 3CLpro inhibitor against FIPV in CRFK 
cells 
Serial dilutions of GC523 were added to confluent CRFK cells and FIPV was inoculated to the 
cells immediately after addition of the inhibitor. Then the cells were incubated at 37 °C until ex-
tensive cytopathic effects were observed. FIPV titer at each dilution of GC523 was determined 
by the TCID50 method. The dose-dependent inhibition curve was plotted using GraphPad Prism 
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The 50% cytotoxicity concentration and the 50% effective concentration are the mean ± standard 
error of the means (SEM) from at least three independent FRET assays.  
*Published previous data [141] 
Inhibitor CC50±SEM (µM) EC50±SEM (µM) 
GC376 >150 0.05 ± 0.04 
GC523 >150 0.07 ± 0.02 
GC543 >150 0.07 ± 0.06 
GC551 >150 0.02 ± 0.06 
GC583 >100 0.09 ± 0.01 
GC587 >100 0.05 ± 0.02 
GC591 >150 0.55 ± 0.23 
GC597 >150 0.04 ± 0.01 
GC772 >150 0.36 ± 0.12 
GC774 >150 0.39 ± 0.03 
NPI52 70.29 ± 5.6 *    0.02 ± 0.01 * 




FRCoV infections in some ferrets can develop into a fatal systemic disease resembling FIP. 
MCoV infections are not fatal but affect the body condition and pelt quality of minks. However, 
there are no treatments available for these viral infections. FRCoV and MCoV are classified in 
the same group of coronaviruses as FIPV, which is alphacoronaviruses. We have previously re-
ported potent 3CLpro inhibitors against FIPV in vitro and in vivo [138-142]. Here, we evaluated 
a focused library of 3CLpro inhibitors against FRCoV and MCoV and determined their struc-
ture-function relationship to identify potent 3CLpro inhibitors for these viruses for the first time. 
We also investigated the conservation of the 3CLpro structure in these coronaviruses using 3D 
homology models in comparison to FIPV 3CLpro crystal structure.  
 
We used FRET assay to assess the effectiveness of the inhibitors against recombinant 3CLpros 
of FRCoV and MCoV. Quencher FRET assay has been used in many studies to assess the activi-
ty of inhibitors. The FRET substrate is a peptide with a cleavage site that is recognized by 
3CLpro and consists of a fluorescent label and a quencher at opposite sides to assess protease 
cleavage [205]. Fluorescence donor and quencher have nearly overlapping emission and absorp-
tion spectrums, respectively. Thus, activity of the protease can be determined by emission of flu-
orescence when the substrate peptide is cleaved, releasing the quencher. The activity of inhibi-




The 3CLpro is essential for the replication of coronaviruses and highly conserved among coro-
naviruses, thus, it is a widely studied therapeutic target. 3CLpro cleaves 8-11 sites in the C ter-
minal end of coronavirus polyproteins to release non-structural proteins for replication [50, 51]. 
The sequence –P3–P2–P1↓P1′–P2′–P3′– denotes the residues spanning the cleavage sites in the 
polyproteins from the N to C terminus and cleavage occurs between P1-P1’ [36, 49]. Substrate 
specificity is mainly determined by P1, P2 and P1’ sites, where P1 is exclusively Glutamine and 
P1’ is a small non-charged residue such as Serine or Alanine while Leucine occupies P2 [36, 49, 
51, 60, 61]. These preferences of residues are important in designing inhibitors for coronavirus 
3CLpro.  
 
Many 3CLpro inhibitors have been reported for coronavirus 3CLpros including peptido-mimetic 
inhibitors [55, 139-141, 192, 214, 243-245]. The 3CLpro inhibitors in this study are dipeptidyl 
and tripeptidyl peptidomimetic inhibitors and comprise a Glutamine surrogate resembling P1, a 
cap at R1 which links to the backbone via R2, R3 resembling P2 and a R4 warhead which inter-
acts with the nucleophilic Cys144 in 3CLpro [140, 220]. Different moieties were incorporated at 
R1, R2, R3 and R4 sites to assess the effect of specific structural groups on anti-3CLpro activity. 
Efficacy of GC376 against FIPV has already been reported in experimentally infected cats and in 
a field trial on cats with acquired FIP.  
 
In our study, GC376 showed increased effectiveness for FIPV 3CLpro in comparison to the ac-
tivity for FRCoV and MCoV 3CLpros, but the IC50s of GC376 for all three 3CLpros are not 
markedly different. GC523, GC543, GC551, GC583, GC587 and GC597 showed similar activi-
ties for all three 3CLpros with IC50s at submicromolar range. Among these inhibitors, the most 
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potent dipeptidyl inhibitor against FRCoV and MCoV 3CLpros was GC587. In addition, the sin-
gle tripeptidyl inhibitor in this study (NPI52), showed increased activity against all three 
3CLpros similar to GC587. However, previous studies by our lab group have shown that dipep-
tidyl inhibitors have higher absorption/retention time in cats than tripeptidyl inhibitors [138].  
 
Multiple amino acid sequence alignment of 3CLpros of FIPV, FRCoV and MCoV strains re-
vealed that these coronaviruses show conservation in the catalytic residues as well as in the key 
residues that may interact with GC376. Although it is difficult to determine the exact residues 
that interact with the inhibitor in each 3CLpro without studying the crystal structures, the struc-
tural homology in the 3D models suggests that these residues are likely to contribute to form 
bonds with GC376 in 3CLpros of ferret and mink coronaviruses.  
 
FRCoV and MCoV 3CLpro homology models were highly homologous to each other and to 
FIPV and TGEV 3CLpros. The slight differences in the orientations of the side chains in these 
residues in 3CLpros of FRCoV and MCoV in comparison to FIPV 3CLpro may be responsible 
for the differences in the IC50 values observed for FRCoV, MCoV and FIPV 3CLpro. However, 
co-crystal 3CLpro structures of FRCoV and MCoV with an inhibitor need to be generated to de-
termine the exact interactions with the inhibitors and the structures of FRCoV and MCoV 
3CLpros. 
 
Since mink and ferret coronaviruses grow poorly in cell culture [145, 149, 150, 160], we evalu-
ated the antiviral activity of these inhibitors against FIPV in cell culture. All the inhibitors 
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demonstrated submicromolar EC50s against FIPV in CRFK cells, confirming that the inhibitors 
efficiently penetrate and inhibit FIPV replication in cells with negligible levels of cytotoxicity.  
 
In conclusion,  we investigated the structural requirements for 3CLpro inhibitors for FRCoV and 
MCoV 3CLpros in vitro and identified inhibitors of recombinant 3CLpros of these coronaviruses 
using FRET assay. The identified potent inhibitors will be further studied for the development of 
























 Characterization of mutations in 3C-like protease of feline coro-3
navirus from a cat with feline infectious peritonitis treated with a 
3C-like protease inhibitor 
3.1 Abstract 
 
A fatal systemic infection in cats known as feline infectious peritonitis (FIP) is caused by feline 
infectious peritonitis virus (FIPV), which is a virulent biotype of feline coronavirus (FCoV). 
There are no effective commercial vaccines or therapeutics for FIP. We have previously con-
ducted a field trial to assess the efficacy of GC376, which is a highly potent coronavirus 3C-like 
protease (3CLpro) inhibitor, in client-owned cats with FIP. Comparison of FCoV 3CLpro amino 
acid sequences from the pre- and eight months post-treatment samples in one cat showed amino 
acid changes of N25S, A252S and K260N in 3CLpro in the post-treatment sample, although the 
cat did not clinically show evidence of drug resistance. To characterize the effect of these amino 
acid changes in FCoV 3CLpro on its susceptibility to GC376, we expressed recombinant 
3CLpros carrying the amino acid changes and assessed their susceptibility against GC376 by us-
ing fluorescence resonance energy transfer (FRET) assay. The FRET assay revealed that N25S, 
but not other amino acid changes, reduces the activity of 3CLpro against GC376, but with a 
moderate fold change (<2) in the 50% inhibitory concentration compared to that of the pre-






Feline coronavirus (FCoV) infects members of the Felidae family, including domestic and wild 
cats. Feline enteric coronavirus (FECV) causes mild enteritis in cats and is a widespread, highly 
transmissible pathogen among cats especially in catteries and multi-cat households. Feline infec-
tious peritonitis virus (FIPV) is a virulent biotype of FCoV which usually causes feline infectious 
peritonitis (FIP) in cats [80]. FIP is a 100% fatal systemic infection and occurs in kittens and 
young cats (6-24 months) [84, 96]. Two clinical forms have been identified for FIP. Wet form is 
characterized by the presence of chest or abdominal effusions and dry form is characterized by 
no or little effusion in the body cavities. Dry form can progress into wet form. FIP is character-
ized by granulomatous lesions that occur in various organs including kidneys, liver and central 
nervous system (CNS) [96, 102, 246]. No effective commercial vaccines or antiviral treatments 
are available for FIP.  
 
Viral proteases have been targeted for the development of antiviral therapeutics and commercial 
viral protease inhibitors are available for a number of important human viral infections, including 
hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The 3C-like protease 
(3CLpro) is the main protease of coronaviruses and processes viral polyproteins into mature viral 
proteins. Thus, 3CLpro is essential for viral replication [36]. Our group has previously reported 
3CLpro inhibitors for FIPV [139-141] and showed that 3CLpro inhibitor GC376 is highly effec-
tive in cats experimentally infected with FIPV [138]. Furthermore, we recently reported a field 
trial of GC376 in client-owned cats with naturally-occurring FIP. In the trial, clinical remission 
was rapidly induced in all cats except one [142]. Many chronic cases relapsed on discontinuation 
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of antiviral treatment of varying durations and some of them were retreated [142]. However, 
those cats that received one or more rounds of antiviral treatment over a period of several months 
did not show reduced susceptibility to antiviral treatment. Analysis of the amino acid sequence 
of FCoV 3CLpro collected at 236 days post-treatment from one cat in the field trial showed ami-
no acid changes of N25S, A252S and K260N in the lungs and spleen and N25S and K260N in 
the kidney, compared to that of pre-treatment FCoV 3CLpro [142]. To characterize the effect of 
these amino acid changes in FCoV 3CLpro on their susceptibility to GC376, we expressed re-
combinant wild-type (pre-treatment) 3CLpro and 3CLpros carrying the amino acid changes and 
compared their susceptibility against GC376 by using fluorescence resonance energy transfer 
(FRET) assay.  
 




CT10 is an 18 month old, castrated male Himalayan cat with wet FIP on admission [142]. The 
clinical signs included lethargy, loss of appetite, abdominal effusion and enlarged colonic lymph 
node. He had been treated with prednisolone prior to enrolling in the field trial. In the trial, he 
received GC376 subcutaneously at 10 to 30 mg/kg/injection for nine weeks and the treatment 
was discontinued at clinical remission. He relapsed after a month with fever and lethargy. Sec-
ond round of treatment was initiated with GC376 at 7.5 to 15 mg/kg/injection which lasted for 12 
weeks. He was in clinical remission at the time of discontinuation of the second round of antivi-
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ral treatment. He then relapsed with typical intra-abdominal lesions without neurological signs 
and was euthanized. The time between the initial treatment and euthanasia was 236 days [142].  
 
3.3.2 Analysis of clinical samples from CT10  
 
Pre-treatment ascites and necropsy tissue samples were collected from CT10. A small fraction of 
ascites (1 ml) was diluted in 4 ml of PBS containing 10 units/ml heparin and was centrifuged. 
The cell pellet was re-suspended in 500 µl of RNAlater (Life Technologies, NY, USA) and kept 
overnight at 4 °C. Following the overnight incubation, the cell pellet was collected by centrifuga-
tion and was stored at -20 °C. The necropsy tissues were cut into small pieces (less than 0.5 cm) 
and added into 5 volumes of RNAlater and kept overnight at 4 °C. Following the overnight incu-
bation, the tissue samples were centrifuged at 13000 rpm for 5 min, the supernatant was removed 
and the pellet was stored at -70 °C.  
 
FCoV RNA was extracted from the macrophages in the cell pellet from pre-treatment ascites and 
the processed necropsy tissue samples using RNeasy mini kit (Life Technologies, Carlsbad, CA) 
and cDNA were synthesized using Superscript III first strand synthesis kit (Invitrogen, Carlsbad, 
CA) with the primer 570R (Table 3-1). The 3CLpro region was amplified by RT-PCR using pri-
mers 576F and 578R (Table 3-1) for sequencing. The 3CLpro amino acid sequences were 
aligned using Clustal Omega multiple sequence alignment program (https://www.ebi.ac.uk/) and 
CLC sequence viewer 8 program (https://www.qiagenbioinformatics.com/) to analyze the amino 




3.3.3 Expression and purification of recombinant FCoV 3CLpros from CT10  
 
The full length cDNA of FCoV 3CLpro from pre-treatment sample was amplified by RT-PCR 
using primers 571F and 307R. The amplified fragments were inserted into pET28a (+) vector 
(GenScript, Piscataway, NJ). The vector was then transformed into JM109 competent cells 
(Promega, Madison, WI), which was plated with kanamycin (50mg/mL). Plasmid DNA was ex-
tracted from selected colonies by using Wizard™ SV plasmid DNA purification system 
(Promega, Madison, WI), and plasmids were sequenced to confirm the presence of the inserted 
3CLpro gene. Then these plasmids were used for site directed mutagenesis. Single (N25S or 
A252S or K260N), double (N25S+K260N) and triple (N25S+A252S+K260N) amino acid 
changes were incorporated by using the QuickChange II site-directed mutagenesis kit (Agilent 
Technologies, Santa Clara, CA) following the manufacturer’s instructions. Plasmid DNA was 
extracted from selected colonies with Wizard™ SV plasmid DNA purification system (Promega, 
Madison, WI). Following confirmation of the plasmids for desired mutations, the clones were 
transformed into Escherichia Coli BL21 cells (Invitrogen, Carlsbad, CA) for expression of 
3CLpro. Protein expression was induced in Luria Bertani broth by 1mM isopropyl β-D-
thiogalactopyranoside (IPTG) for 4-6 hrs at 37 °C in a shaking incubator. The cells were then 
harvested and centrifuged. The 3CLpros were purified using Ni-NTA affinity columns (QI-
AGEN, Valencia, CA) and stored at -80 °C. The primer sequences used for RT-PCR and cloning 
are indicated in Table 3-1. Nomenclature of the recombinant 3CLpros and primers used for site-
directed mutagenesis are indicated in Table 3-2. In the following text, designations of the 
3CLpro from the pre-treatment ascites are WT, 3CLpros with single amino acid changes will be 
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25, 252 and 260 and 3CLpros with double and triple amino acid changes will be 25+260 and 
25+252+260, respectively.   
 
Table 3-1: Primer sequences used in RT-PCR and cloning of 3CLpro  
 
Primer  Sequence 
307R  5’ AAT TCT CGA GGC GGC CGC TCA CTG AA 3’ 
570R  5’ TAA TAC TAA CAA ATG TCG GGT TAA T 3’ 
571F  
 
5’ AAT TTC TAG AAA GGA GAT ATA CCA TGC ATC ATC ATC ATC ATC ATT CTG 
GAT TGC GAA A 3’ 
576F  5’ CTT GTT ATG CTC ATT TGG GTA AGG 3’ 
















Table 3-2: Nomenclature of recombinant 3CLpros and the primer sequences used in site 
directed mutagenesis 
 
Amino acid change Nomenclature Mutagenesis primers 
Pre-treatment (wild type) WT None 
N25S 25 
688F (5’ AAGGGTTGCTTATGGTAATAGTGTTCTCAATGGT 3’) 
688R (5’ ACCATTGAGAACACTATTACCATAAGCAACCCTT 3’) 
A252S 252 
686F (5’ TTTTAACATGTTGGCCTCAAAAACTGGTTACAGT 3’) 
686R (5’ ACTGTAACCAGTTTTTGAGGCCAACATGTTAAAA 3’) 
K260N 260 
687F (5’ GGTTACAGTGTTGAAAACTTGCTTGAGTGTATT 3’) 
687R (5’ AATACACTCAAGCAAGTTTTCAACACTGTAACC 3’) 
N25S+K260N 25+260 688F, 688R + 687F, 687R 
N25S+A252S+K260N 25+252+260 688F, 688R + 687F, 687R + 686F, 686R 
  
3.3.4 FRET assay  
 
FRET assay buffer containing 120mM NaCl, 4mM DTT, 50mM HEPES and 30% Glycerol at 
pH 6.0 was used in the FRET assay. First, activities of the recombinant 3CLpros were deter-
mined. Serial dilutions of each 3CLpro were prepared in 25µl of assay buffer. Each dilution was 
added to Corning™ Falcon™ 96-well imaging microplate containing 25µl of buffer containing 
fluorogenic substrate (dabacyl-KTSAVLQ/SGFRKME-edans), which was incubated at 37 ˚C for 
30 min. Fluorescence readings were recorded at 30 min of incubation using a fluorescence mi-
croplate reader (FLx800, Biotek, Winooski, VT). The background fluorescence (reading from 
substrate only well) was subtracted from each reading. The readings of each 3CLpro were com-
53 
pared by one-way ANOVA with Tukey’s post hoc test (Graphpad Prism, version 6.07, La Jolla, 
CA) (p<0.05).  
 
After determining the activities of the recombinant 3CLpros, inhibition assay with GC376 and 
NPI52 were conducted. Synthesis of 3CLpro inhibitors GC376 [140] and NPI52 [218] were pre-
viously reported by our group. The 10mM stock solutions and serial dilutions of GC376 and 
NPI52 were prepared in DMSO. Serial dilutions of each inhibitor were pre-incubated with 25µl 
of 3CLpro mixed in assay buffer for 30 min at 37 °C. Each mixture was combined with 25 µl of 
substrate in assay buffer and further incubated at 37 °C for 30 min. Fluorescence readings were 
recorded at 30 min and the background fluorescence was subtracted from each reading to obtain 
relative fluorescence units. Inhibitor concentration that gives a 50% inhibitory concentration 
(IC50) was determined by using non-linear regression using GraphPad Prism software (Graphpad 
Prism, version 6.07, La Jolla, CA). The IC50s of inhibitors for 3CLpros with amino acid changes 
were statistically compared with that of WT-3CLpro by two-tailed student’s T test (p<0.05).   
 
3.3.5 3D homology models of FCoV 3CLpros from CT10 
 
3D homology models of WT-3CLpro and 3CLpros with amino acid changes were constructed 
using Easy Modeller program (version 4.0) [247] using FIPV 3CLpro crystal structures (PDB 
accessions 4ZRO and 5EU8) as templates. The modelled structures were superimposed with 
TGEV 3CLpro-GC376 crystal structure (PDB accession 4F49) [140] to compare the inhibitor 
binding site. TGEV 3CLpro-GC376 crystal structure was previously reported by our group 
[140]. The amino acids in the TGEV 3CLpro that interact with GC376 are T47, F139, C144, 
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H162, H163 and E165 [140]. 3CLpros of TGEV and FIPV share an amino acid sequence homol-
ogy of 92.05-93.71%. Crystal structures of TGEV-GC376 and FIPV (PDB accession 4ZRO) 
3CLpros were also superimposed to analyze the inhibitor binding site.  
 
Potential hydrogen bonds formed by N25, A252 and K260 with the neighboring amino acids and 
the alterations in the hydrogen bonds caused by amino acid changes were investigated using 
FIPV 3CLpro crystal structure (PDB accession 4ZRO) and residue interaction network generator 
web application (RING v2.0.1) [248] at a threshold hydrogen bond distance of 3.5 Å. The identi-
fied potential hydrogen bonds were visualized in FIPV 3CLpro crystal structure (4ZRO) by us-




3.4.1 Analysis of FCoV 3CLpro amino acid sequences from CT10 
 
Amino acid changes were identified in 3CLpro sequences from necropsy tissues in comparison 
to pre-treatment sample. The amino acid changes in 3CLpro from kidney were N25S and K260N 
[142]. Lungs and spleen had an additional amino acid change of A252S along with N25S and 
K260N (Fig. 3-1).   
 
We also studied the conservation of the residues at positions 25, 252 and 260 in 3CLpro of 44 
FCoV strains whose 3CLpro sequences are available in Genbank. All these sequences have N at 
25 and A at 252. Out of 44 FCoV strains, 43 strains have K at 260 while one strain (FCoV strain 
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UU54) has R at 260. The residues of TGEV 3CLpro that interact with GC376 (H41, T47, F139, 
C144, H162, H163 and E165 [140]) are conserved in all the 3CLpro sequences and in the same 
location as in TGEV 3CLpro.  
 
 
In comparison to pre-treatment ascites, lungs and spleen had amino acid changes N25S, A252S 
and K260N while kidneys had N25S and K260N. The C-terminal residues 294-302 of the 





Figure 3-1: Multiple amino acid sequence alignment of FCoV 3CLpros from pre-treatment 
sample and necropsy tissues of CT10 
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3.4.2 FRET assay with the recombinant 3CLpros and 3CLpro inhibitors  
 
All 3CLpros showed statistically similar activities (Fig. 3-2), indicating that the amino acid 
changes may not interfere with the activity of these 3CLpros.  
 
Our inhibition assay results indicated that, in comparison to that of WT-3CLpro, 3CLpros with 
amino acid changes at 25, 25+260 and 25+252+260 have increased IC50 of GC376 by 1.38, 1.53 
and 1.68 folds, respectively (Table 3-3). The IC50s for 3CLpros with amino acid changes at 25, 
25+260 and 25+252+260 were statistically increased from the IC50 for WT-3CLpro (Fig. 3-3A), 
and no statistical difference in IC50s was observed amongst 3CLpros with 25, 25+260 and 
25+252+260. IC50s of GC376 for 3CLpros with only single amino acid changes at 252 or 260 
were similar to that of WT-3CLpro with no statistical difference (Table 3-3). These results indi-
cate that the presence of N25S only slightly decreases the inhibitory activity of GC376 (<2 
folds).  
 
NPI52, a 3CLpro inhibitor, was previously reported by our group for its antiviral effects against 
FIPV in cell culture [141] and was included in the study to determine if the amino acid changes 
generated against GC376 affect the activity of NPI52. IC50s of NPI52 for 3CLpros with amino 
acid changes at 25, 252 and 25+260 were increased by 1.54, 1.24 and 1.33 folds, respectively, 
when compared to that of WT-3CLpro. However, IC50s of NPI52 for all the 3CLpros with amino 
acid changes were not statistically different from that of WT-3CLpro (Fig. 3B). Therefore, these 





Figure 3-2: Activity of the recombinant 3CLpros at 30 min in the absence of 3CLpro inhib-
itors 
The 3CLpros were incubated with the fluorogenic substrate in assay buffer and fluorescence 
readings were measured at 30 min after incubation. Each bar represents the mean ± standard er-
ror of means (SEM) of fluorescence units at 30 min from at least three independent FRET as-
says. Statistical difference between mean fluorescence units was investigated by one-way ANO-
VA with Tukey’s post hoc test (Graphpad Prism, version 6.07, La Jolla, CA) (p<0.05). The ac-




































WT  None 1 1 
Single  
N25S 1.38 1.54 
A252S 1.15 1.24 
K260N 1.05 0.98 
Double  N25S+K260N 1.53 1.33 
Triple  N25S+K260N+A252S 1.68 1.06 
 
































































Figure 3-3: Effects of GC376 and NPI52 on recombinant 3CLpros in FRET assay 
Each 3CLpro was incubated with serial dilutions of (A) GC376 or (B) NPI52 for 30 min at 37 °C 
before adding the fluorogenic substrate to the mixture. Fluorescence readings were measured af-
ter 30 min of incubation of the mixture and relative fluorescence units were calculated by sub-
tracting the background fluorescence from each reading. IC50 was determined using non-linear 
regression using GraphPad Prism software (Graphpad Prism, version 6.07, La Jolla, CA). Each 




pendent FRET assays. Statistical difference was determined by two-tailed student’s T test 
(P<0.05). * indicates statistically significant difference from the WT.  
 
3.4.3 The 3D structure models of the FCoV 3CLpros from CT10  
 
Crystal structures of FIPV 3CLpro showed that N25 lies close to the active site while A252 and 
K260 are in domain III, close to the C-terminus (Fig. 3-4A). Superimposing the 3D model of 
WT-3CLpro or FIPV 3CLpro crystal structure with TGEV 3CLpro-GC376 crystal structure 
showed that the residues potentially interacting with GC376 in each 3CLpro are in close prox-
imity to the same residue in other 3CLpros  (Fig 3-4B and 3-4C).   
 
We explored the potential hydrogen bond interactions formed by N25, A252 and K260 with 
neighboring amino acids and the effect of amino acid changes S25, S252 and N260 on these in-
teractions using FIPV 3CLpro crystal structure (PDB accession 4ZRO). It is predicted by RING 
that N25 forms two hydrogen bonds with Y22 at bond distances of 3.029 and 3.131 Å and single 
hydrogen bonds with H41 (catalytic residue) and A44 (Fig. 3-5A) with the bond distances 3.486 
and 2.615 Å, respectively. It is predicted that 3CLpro with N25S retains the hydrogen bonds with 
Y22, but loses the hydrogen bonds with H41 and A44 (Fig.3-5D). In 3CLpro, A252 possibly 
forms single hydrogen bonds with N248 and M249 (Fig. 3-5B) at bond distances of 2.810 and 
3.432 Å, respectively. A252S may not disrupt these single hydrogen bonds (Fig. 3-5E). It is like-
ly for K260 to form hydrogen bonds with S257, G263 and C264 (Fig. 3-5C) with bond distances 
of 3.226, 3.267 and 3.037 Å, respectively.  K260N may maintain these hydrogen bonds (Fig. 3-




Figure 3-4: The locations of the amino acid changes in the 3CLpro 
(A) The locations of amino acid changes (N25, A252 and K260 in green) and catalytic residues 
H41 and C144 (red) are depicted in the FIPV 3CLpro crystal structure (PDB accession number 
4ZRO). N25 is close to the active site while A252 and K260 are in domain III near the C termi-
nus. Active site of the superimposed crystal structure of TGEV 3CLpro-GC376 (teal) and (B) 
crystal structure of FIPV 3CLpro (slate) or (C) homology model of WT-3CLpro (pink) indicate 
that N25 is in close proximity to the catalytic residues and  residues that interact with GC376 
(H47, F139, C144, H162, H163 and E165 [140]). GC376 (red) is shown as a red stick. 
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Figure 3-5: The potential hydrogen bonds of N25, A252 and K260 in WT and the altera-
tions in hydrogen bonds with amino acid changes S25, S252 and N260 in 3CLpro. 
The potential hydrogen bond interactions of N25S, A252S and K260N were investigated in FIPV 
3CLpro crystal structure (4ZRO) using RING program (v2.0.1) [248] with a threshold distance 
of 3.5 Å, and visualized in PyMol. The potential hydrogen bonds formed by (A) N25, (B) A252 
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and (C) K260 with the neighboring amino acids in FIPV 3CLpro are shown with the distance 
measurements in Å. The amino acid changes of (D) N25S, (E) A252S and (F) K260N may retain 




RNA viruses can rapidly evolve as they lack the intrinsic proof reading activity, generating qua-
si-species. Selective pressure such as antiviral treatment can increase the population of existing 
resistant variants or drive the generation of new resistant variants [223, 225, 249]. The resistant 
variants may display higher, lower or same replication efficiency as the wild type virus and the 
variants with higher replication efficiency can establish in the population [225, 226]. Ease of 
generating mutations that confer resistance, replicative fitness of the resistant variants, immune 
response by the host, non-compliance to antiviral treatment and prolonged antiviral treatment are 
important factors that contribute to antiviral resistance [225, 231, 250]. Increased viral replica-
tion resulting in disease progression and failure to respond to treatment indicate clinical antiviral 
resistance.  
 
Coronavirus 3CLpro is an attractive target for the development of antiviral drugs as 3CLpro is 
highly conserved among coronaviruses and important for virus replication. 3CLpro consists of 
three domains, I, II and III [51]. The proteolytic cleavage of the virus polyprotein occurs at the 
active site which is in a chymotrypsin-like fold composed of two β barrels between domain I and 
II [48, 52, 55]. The active site contains a highly conserved catalytic dyad; nucleophilic C144 and 
an acid-base donor H41 [36, 50-53, 55, 56, 58]. The active form of 3CLpro is reported to be a 
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dimer [59, 251] and interactions between domain III and N-terminal residues 1-7 of domain I 
between monomers are important for the dimerization [51, 52, 54-56, 58, 59, 252].   
 
Antiviral resistance for 3CLpro inhibitors has not been widely studied in coronaviruses. A previ-
ous study by our group reported that emergence of FIPV resistant to GC376 was not observed 
even up to 20 passages in CRFK cells [138], suggesting that GC376 has a high barrier for re-
sistance. But, FIPV developed resistance to NPI52 before 10 passages in cell culture, resulting in 
a 15 fold increase in the 50% effective concentration (EC50) at passage number 10 [138]. Single 
amino acid change of S131C was identified in the resistant viruses against NPI52 which was in 
domain II, away from the active site [138]. Murine hepatitis virus (MHV) is a murine corona-
virus infecting mice. MHV developed rapid resistance at four passages in the presence of 
3CLpro inhibitor GRL-001, generating single (T26I, D65G or D65A) and double (T26I/D65G or 
T26I/A298D) amino acid changes in 3CLpro [233]. However, the resistant variants with 
T26I/D65G amino acid changes replicated slowly and were attenuated in mice [233]. The amino 
acid changes T26I and D65G are in domain I and close to the active site, while A298D is in do-
main III near the C terminal end of 3CLpro. The authors suggested that T26I and D65G may al-
ter the conformation of the active site and affect binding of the inhibitor, whereas A298D may 
affect dimerization [233]. Thus, these studies showed that residues that are in close proximity to 
the active site as well as residues at a distance may affect the function of 3CLpro, and 3CL inhib-
itors may have varying genetic barriers for resistance. 
  
The three amino acid changes identified in this study were in highly conserved positions in 
FCoV 3CLpro. We observed statistically significant, but marginal decrease (<2-fold) in the in-
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hibitory activity of GC376 for 3CLpros with amino acid change N25S, alone or in combination 
with A252 and K260N. N25 is close to the active site and forms potential interactions with H41 
and A44, which are lost with N25S. This loss of interactions might slightly affect the structure of 
the active site in 3CLpro, thereby affecting GC376 activity. However, only marginal decrease in 
activity of GC376 was observed for 3CLpros with N25S in enzyme assay and this observation 
may also explain the lack of observance of clinical resistance for CT10 in the field study. 
3CLpros with only A252S or K260N did not affect the activity of GC376.  
 
We did not observe marked changes in the activity of NPI52 against any of the recombinant 
3CLpros. NPI52 is a tripeptidyl compound and has an additional peptide bond and a 1-
napththylalanine moiety in comparison to the structure of GC376. The amino acid changes in 
3CLpro did not affect the inhibitory activity of NPI52.  
 
In summary, the amino acid changes in 3CLpro did not have marked reduction in the activity of 
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